Jason Drew Smith

CIK: 0001821479

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)10 (45.5%)

Position reduction

Option Exercises (M)10 (45.5%)

Derivative conversions

Awards (A)2 (9.1%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

URGN

UroGen Pharma Ltd.

Officer

Discretionary Trading P&L

Holdings

Transaction History (22 total)

URGN
UroGen Pharma Ltd.
Sep 8, 2026
Sale(S)
Direct
1.5K shares at avg. $42.54$65K
URGN
UroGen Pharma Ltd.
Sep 7, 2026
Exercise(M)
Direct
3.3K shares-
URGN
UroGen Pharma Ltd.
Feb 3, 2026
Sale(S)
Direct
3.2K shares at avg. $19.69$63K
URGN
UroGen Pharma Ltd.
Feb 3, 2026
Sale(S)
Direct
2.7K shares at avg. $19.69$52K
URGN
UroGen Pharma Ltd.
Feb 3, 2026
Sale(S)
Direct
1.6K shares at avg. $19.69$32K
URGN
UroGen Pharma Ltd.
Jan 31, 2026
Exercise(M)
Direct
5.5K shares-
URGN
UroGen Pharma Ltd.
Jan 31, 2026
Award(A)
Restricted Stock Units
Direct
32.6K shares-
URGN
UroGen Pharma Ltd.
Jan 31, 2026
Exercise(M)
Direct
6.7K shares-
URGN
UroGen Pharma Ltd.
Jan 31, 2026
Exercise(M)
Direct
3.3K shares-
URGN
UroGen Pharma Ltd.
Sep 8, 2025
Sale(S)
Direct
1.5K shares at avg. $19.11$29K
URGN
UroGen Pharma Ltd.
Sep 7, 2025
Exercise(M)
Direct
3.3K shares-
URGN
UroGen Pharma Ltd.
Jul 28, 2025
Sale(S)
Direct
7.5K shares at avg. $19.14$144K
URGN
UroGen Pharma Ltd.
Jul 28, 2025
Exercise(M)
Direct
16.5K shares-
URGN
UroGen Pharma Ltd.
Jan 31, 2025
Exercise(M)
Direct
5.5K shares-
URGN
UroGen Pharma Ltd.
Jan 31, 2025
Sale(S)
Direct
3.4K shares at avg. $11.14$37K
URGN
UroGen Pharma Ltd.
Jan 31, 2025
Sale(S)
Direct
1.3K shares at avg. $11.14$14K
URGN
UroGen Pharma Ltd.
Jan 31, 2025
Exercise(M)
Direct
2.5K shares-
URGN
UroGen Pharma Ltd.
Jan 31, 2025
Exercise(M)
Direct
6.7K shares-
URGN
UroGen Pharma Ltd.
Jan 31, 2025
Sale(S)
Direct
2.8K shares at avg. $11.14$31K
URGN
UroGen Pharma Ltd.
Jan 31, 2025
Award(A)
Restricted Stock Units
Direct
10K shares-
URGN
UroGen Pharma Ltd.
Sep 9, 2024
Exercise(M)
Direct
3.3K shares-
URGN
UroGen Pharma Ltd.
Sep 9, 2024
Sale(S)
Direct
1.5K shares at avg. $13.08$20K

		Type	Shares	Price		Ownership
Sep 8, 2026	URGN UroGen Pharma Ltd.	Sale(S)	1,519	$42.54	$64,618	Direct
Sep 7, 2026	URGN UroGen Pharma Ltd.	Exercise(M)	3,334	-	$0	Direct
Feb 3, 2026	URGN UroGen Pharma Ltd.	Sale(S)	3,217	$19.69	$63,343	Direct
Feb 3, 2026	URGN UroGen Pharma Ltd.	Sale(S)	2,654	$19.69	$52,257	Direct
Feb 3, 2026	URGN UroGen Pharma Ltd.	Sale(S)	1,608	$19.69	$31,662	Direct
Jan 31, 2026	URGN UroGen Pharma Ltd.	Exercise(M)	5,500	-	$0	Direct
Jan 31, 2026	URGN UroGen Pharma Ltd.	Award(A) Restricted Stock Units	32,609	-	-	Direct
Jan 31, 2026	URGN UroGen Pharma Ltd.	Exercise(M)	6,667	-	$0	Direct
Jan 31, 2026	URGN UroGen Pharma Ltd.	Exercise(M)	3,333	-	$0	Direct
Sep 8, 2025	URGN UroGen Pharma Ltd.	Sale(S)	1,520	$19.11	$29,047	Direct
Sep 7, 2025	URGN UroGen Pharma Ltd.	Exercise(M)	3,333	-	-	Direct
Jul 28, 2025	URGN UroGen Pharma Ltd.	Sale(S)	7,522	$19.14	$143,971	Direct
Jul 28, 2025	URGN UroGen Pharma Ltd.	Exercise(M)	16,500	-	-	Direct
Jan 31, 2025	URGN UroGen Pharma Ltd.	Exercise(M)	5,500	-	-	Direct
Jan 31, 2025	URGN UroGen Pharma Ltd.	Sale(S)	3,354	$11.14	$37,364	Direct
Jan 31, 2025	URGN UroGen Pharma Ltd.	Sale(S)	1,258	$11.14	$14,014	Direct
Jan 31, 2025	URGN UroGen Pharma Ltd.	Exercise(M)	2,500	-	-	Direct
Jan 31, 2025	URGN UroGen Pharma Ltd.	Exercise(M)	6,667	-	-	Direct
Jan 31, 2025	URGN UroGen Pharma Ltd.	Sale(S)	2,767	$11.14	$30,824	Direct
Jan 31, 2025	URGN UroGen Pharma Ltd.	Award(A) Restricted Stock Units	10,000	-	-	Direct
Sep 9, 2024	URGN UroGen Pharma Ltd.	Exercise(M)	3,333	-	$0	Direct
Sep 9, 2024	URGN UroGen Pharma Ltd.	Sale(S)	1,521	$13.08	$19,895	Direct

1-22 of 22 transactions

About Smith Jason Drew

Smith Jason Drew (SEC CIK 0001821479) files insider reports with the SEC as General Counsel of UroGen Pharma Ltd. (URGN).

Signal8 holds 6 ownership filings by Smith Jason Drew, all Form 4s, filed between Sep 12, 2024 and Sep 9, 2026. Those filings report 22 transactions, from Sep 9, 2024 to Sep 8, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Smith Jason Drew's filings is in PRINCETON, NJ.

Recent filings by Smith Jason Drew

Sep 8, 2026: Open-market sale of URGN shares (Form 4, code S).
Sep 7, 2026: Option exercise of URGN shares (Form 4, code M).
Feb 3, 2026: Open-market sales of URGN shares (3 lines, Form 4, code S).
Jan 31, 2026: Option exercise of URGN shares (Form 4, code M).
Jan 31, 2026: Grant or award of URGN derivative securities (Form 4, code A).

Other insiders filing for UroGen Pharma Ltd. (URGN)

Degnan Chris, Chief Financial Officer
Schoenberg Mark, Chief Medical Officer
Robinson James A. Jr., Director
Wildman Daniel George, Director
Holden Stuart, Director
BUTITTA CYNTHIA M, Director

How to read Form 4 transaction codes